Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy...

Area of Science:

• Oncology
• Endocrinology
• Cancer Biology

Background:

• Androgen ablation is a primary treatment for recurrent prostate cancer.
• Prostate cancers often develop resistance to androgen suppression, leading to metastasis.
• Preclinical studies suggest prostate cancer cells regulate androgen signaling for growth.

Purpose of the Study:

• To review preclinical evidence on prostate cancer's adaptation to androgen signaling.
• To evaluate the efficacy of high-dose testosterone (HDT) therapy in castration-resistant prostate cancer (CRPC).
• To explore potential vulnerabilities in treatment-resistant prostate cancer.

Main Methods:

• Review of decades of preclinical studies on prostate cancer and androgen signaling.
• Analysis of laboratory data on cancer cell adaptation to low-androgen environments.
• Examination of clinical trial data from HDT therapy in CRPC patients.

Main Results:

• Preclinical models indicate prostate cancer cells optimize growth by titrating androgen signaling.
• Adaptations for low-androgen survival may sensitize cancer to androgen restoration, particularly at high doses.
• Clinical trials suggest HDT offers benefits in cancer response and quality of life for a subset of CRPC patients.

Conclusions:

• HDT shows clinical benefit in a subset of CRPC patients, warranting further investigation and optimization.
• Prostate cancer inevitably adapts to HDT, similar to androgen deprivation therapy.
• Understanding cancer's adaptive mechanisms to hormonal therapies can reveal vulnerabilities for improved treatment strategies and prolonged survival.